Differential Expression of the Five Somatostatin Receptor Subtypes in Human Benign and Malignant Insulinomas – Predominance of Receptor Subtype 4
- 27 June 2007
- journal article
- research article
- Published by Springer Nature in Endocrine Pathology
- Vol. 18 (2) , 79-85
Abstract
Insulinomas constitute a subgroup of pancreatic endocrine tumors showing B cell differentiation and clinical symptoms related to inappropriate insulin secretion (WHO). Many endocrine tumors express somatostatin receptors (sstrs), which can be visualized by octreotide scintigraphy; however, about half of all insulinomas are reported to be negative. Previous immunohistochemical investigations with antibodies to sstr subtypes 1, 2, 3, and 5 have revealed differences in expression between various neuroendocrine tumors. In the present study, the immunoreactivity to all five human sstr was studied in ten benign and six malignant human insulinomas. Sstr4 was the receptor subtype most frequently expressed in both benign and malignant tumors. A difference in the immunohistochemical sstr5 expression pattern was seen between benign and malignant tumors: Three of the six malignant tumors, but none of the benign tumors, expressed sstr5. The other receptor subtypes were expressed in low numbers with no difference between benign and malignant tumors. The finding of a strong expression of sstr4 in both benign and malignant insulinomas suggests that this receptor subtype could be of importance for diagnostic and therapeutic use.Keywords
This publication has 33 references indexed in Scilit:
- Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomasEndocrine-Related Cancer, 2006
- Expression of Somatostatin Receptor Subtypes 1 to 5 in Tumor Tissue and Intratumoral Vessels in Malignant Endocrine Pancreatic TumorsMedical Oncology, 2003
- Expression of Somatostatin Receptor and Effects of Somatostatin Analog on Pancreatic Endocrine TumorsSurgery Today, 2002
- Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumorsVirchows Archiv, 2002
- Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumoursBritish Journal of Surgery, 2001
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.Journal of Clinical Investigation, 1994
- Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor SubtypeBiochemical and Biophysical Research Communications, 1993
- Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney.Proceedings of the National Academy of Sciences, 1992
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981